Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.38 |
| ▸ | ACACA | Q13085 | 8/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154917 | 1.00 | ACACB (0.38) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL4797081 | 0.89 | CKS1B (0.37) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL3158158 | 0.89 | SLC2A1 (0.36) | CKS1BSKP1SKP2DRD2KCNH2 | |
| SCHEMBL3158168 | 0.89 | SLC2A1 (0.36) | CKS1BSKP1SKP2DRD2KCNH2 | |
| SCHEMBL3148938 | 0.85 | SLC2A1 (0.41) | CKS1BSKP1SKP2KCNH2 | |
| SCHEMBL3149998 | 0.85 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL1076139 | 0.85 | SLC2A1 (0.42) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL1076141 | 0.85 | SLC2A1 (0.42) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL3149203 | 0.82 | CKS1B (0.40) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL13315179 | 0.80 | KCNH2 (0.45) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| EP-2176262-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
| US-20080280892-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| WO-2008128962-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| EP-1954697-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007081597-A2 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | ACACB 1334/4885ACACA 1426/4885CKS1B 2649/4885 |
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | NRDC, NACA, NOP2 | ACACB 2747/4885ACACA 2693/4885CKS1B 1829/4885 |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | ACACB 1755/4885ACACA 2422/4885CKS1B 1345/4885 |
| US-20080280892-A1 | Compounds | NRDC, NACA, NAA50 | ACACB 2421/4885ACACA 2308/4885CKS1B 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.